Photocure har overtatt og startet i Ipsen området

Slettet bruker
PHO 01.10.2020 kl 09:24 1776

Photocure launches European Hexvix operations
Oslo, Norway, 1 October 2020: Photocure ASA (OSE:PHO) today announces the commencement of the sales, marketing and distribution of Hexvix® in the European markets formerly operated by Ipsen Pharma SAS (Ipsen). The successful transition and launch of European Hexvix operations creates a robust platform for accelerated growth and expansion for Photocure.

"We are proud to announce the launch of our European Hexvix operations which will transform Photocure into a strong global business within the diagnosis and treatment of bladder cancer. We have built a successful commercial organization for Hexvix/Cysview in the U.S. and the Nordics. Based on our unique understanding of bladder cancer and its care, our full commercial capabilities to grow and expand these new markets will be applied. As bladder cancer is the most expensive cancer to treat, there is considerable and growing interest in the bladder cancer market in Europe. We see significant opportunities ahead for Photocure,” says Dan Schneider, President and CEO.

Photocure announced in June 2020 that the company had finalized an agreement with Ipsen to regain the commercial rights for Hexvix in selected European and other countries. The rights have been transferred to Photocure with the official launch of the commercial operations beginning today, 1 October 2020.

“We are pleased with the successful Ipsen transition and with the launch of our European commercial operations. The entire European team has worked tirelessly over recent months to ensure we hit the ground running. We have ramped-up and strengthened our commercial organization and established an efficient distribution and third-party logistics network. By applying our experience from the commercial success in the Nordic and the U.S. markets to the European region, Photocure is positioned for accelerated growth and profitability,” says Susanne Strauss, Vice President and General Manager of Europe in Photocure.

Photocure has paid Ipsen EUR 15 million for regaining the Hexvix rights and Ipsen will also receive earn-out payments in the range of 10 -15% of sales (years 1-7 post-transfer) and 7.5% of sales (years 8-10) in the former Ipsen markets.

Confirms key financial targets for the acquired rights

Photocure announced preliminary financial targets for the transaction 27 April 2020. The targets have today been confirmed.

2019 royalty received by Photocure was NOK 61 million excluding IFRS adjustments
Following the transfer of the rights for the Ipsen territories to Photocure, the revenue recognized by Photocure is expected to increase around 3x to 2021 compared to 2019, driven by Photocure being granted the in-market sale in the territories and growth in market penetration
Beyond FY 2021, Photocure is targeting approximately 20-30% annual revenue growth in the former Ipsen territories
NOK 30-35 million in integration and ramp-up costs in 2020. Around NOK 90 million in increased SG&A costs in Europe from FY 2021 and beyond
European operations will be EBIDTA accretive from 2021 and beyond
Market conditions are affected by the COVID-19 virus outbreak. See OSE notification of 7 April 2020 for an in-depth analysis of the risk and effects of the COVID-19 situation, in addition to the trading update 27 April 2020 and the second quarter 2020 presentation and board of directors' report of 17 August 2020.

EBITDA and other alternative performance measures (APMs) are defined and reconciled to the IFRS financial statements as a part of the APM section of the second quarter 2020 financial report on pages 22-23.


https://photocure.com/news/photocure-launches-european-hexvix-operations/
Redigert 20.01.2021 kl 23:52 Du må logge inn for å svare
Computum
01.10.2020 kl 09:43 1726

Photocure igjen på offensiven!
Håper bare at valget i USA blir gjennomført uten betydelige uroligheter. Det vil i såfall kunne gi en ny nedtur både for PHO og for aksjemarkedet.
Redigert 20.01.2021 kl 23:52 Du må logge inn for å svare
sokaratest
01.10.2020 kl 10:14 1656

Fantastiske muligheter for selskapet fremover - globalt selskap med sterk vekst og 40%margin - og så er det noen kinesere som har stor appetitt
Redigert 20.01.2021 kl 23:52 Du må logge inn for å svare
Computum
01.10.2020 kl 12:07 1513

Da ble det "sell on news" igjen. Flott oppgang på formiddag selges raskt ned igjen. Trodde nesten en stund at 100 var innen rekkevidde idag.
Redigert 20.01.2021 kl 23:52 Du må logge inn for å svare
Slettet bruker
01.10.2020 kl 13:03 1426

Tror vi kan regne med at den ganske kjapt henter seg inn igjen.
Etter +7,5% på 64,1 mill igår må man forvente en reaksjon tilbake før ny bølge.
Redigert 20.01.2021 kl 23:52 Du må logge inn for å svare
Computum
01.10.2020 kl 13:37 1377

Når den nå går minus kan man vel regne med nytt shortangrep?
For ellers virker det ikke rasjonelt å selge så "billig" når man har hatt stort handlingsrom til å få bedre betalt det siste døgnet.
Redigert 20.01.2021 kl 23:52 Du må logge inn for å svare
Slettet bruker
01.10.2020 kl 14:00 1343

Mulig, personlig tror jeg shorterne skal slite betydelig med å presse den ned særlig mye.
Momentum er sterkt i aksjen og kjøperne er der.
Vet ikke hva snittkurs ble igår, glemte å sjekke, men det gikk endel på disse nivåene.
Redigert 20.01.2021 kl 23:52 Du må logge inn for å svare
Computum
01.10.2020 kl 14:06 1334

Shortene er ikke nødvendigvis langsiktige. Såvidt jeg har forstått robothandles det nå også short.
Redigert 20.01.2021 kl 23:52 Du må logge inn for å svare
Slettet bruker
01.10.2020 kl 14:09 1324

Mulig Comp. kan for lite om slik handel.
Men Photocure er sterk nå.
Fra morgenrapporten til Investtech idag.

Photocure (PHO) endte på 95.70 kroner etter en oppgang på 7.41%. Aksjen har ikke sluttet på en høyere kurs siden 24. februar. Teknisk ser det også bra ut. Aksjen er trendmessig positiv på mellomlang sikt og en videre oppgang indikeres.
Redigert 20.01.2021 kl 23:52 Du må logge inn for å svare
Computum
01.10.2020 kl 17:18 1149

Dagen begynte eventyrlig. Tror ikke jeg har sett en sterkere dag for min samlede portefølje. Men så endte den likevel godt i minus. Mye kortsiktighet for tiden.
Redigert 20.01.2021 kl 23:52 Du må logge inn for å svare